• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Introducing the Affinity Binder Knockdown Initiative ⿿A public⿿private partnership for validation of affinity reagents
Publication date: March 2016 Source:EuPA Open Proteomics, Volume 10 Author(s): Tove Alm, Emma Lundberg, Mathias Uhlén The newly launched Affinity Binder Knockdown Initiative encourages antibody suppliers and users to join this public⿿private partnership, which uses crowdsourcing to collect characterization data on antibodies. Researchers are asked to share validation data from experiments where gene-editing techniques (such as siRNA or CRISPR) have been used to verify antibody binding. The initiative is launched under the aegis of Antibodypedia, a database designed to allow comparisons and scoring of publicly available...
Source: EuPA Open Proteomics - February 2, 2017 Category: Bioinformatics Source Type: research

Introducing the Affinity Binder Knockdown Initiative —A public–private partnership for validation of affinity reagents
Publication date: March 2016 Source:EuPA Open Proteomics, Volume 10 Author(s): Tove Alm, Emma Lundberg, Mathias Uhlén The newly launched Affinity Binder Knockdown Initiative encourages antibody suppliers and users to join this public–private partnership, which uses crowdsourcing to collect characterization data on antibodies. Researchers are asked to share validation data from experiments where gene-editing techniques (such as siRNA or CRISPR) have been used to verify antibody binding. The initiative is launched under the aegis of Antibodypedia, a database designed to allow comparisons and scoring of publicly avail...
Source: EuPA Open Proteomics - June 17, 2016 Category: Bioinformatics Source Type: research

Introducing the Affinity Binder Knockdown Initiative—A public–private partnership for validation of affinity reagents
Publication date: March 2016 Source:EuPA Open Proteomics, Volume 10 Author(s): Tove Alm, Emma Lundberg, Mathias Uhlén The newly launched Affinity Binder Knockdown Initiative encourages antibody suppliers and users to join this public–private partnership, which uses crowdsourcing to collect characterization data on antibodies. Researchers are asked to share validation data from experiments where gene-editing techniques (such as siRNA or CRISPR) have been used to verify antibody binding. The initiative is launched under the aegis of Antibodypedia, a database designed to allow comparisons and scoring of publicly avail...
Source: EuPA Open Proteomics - January 30, 2016 Category: Bioinformatics Source Type: research

Introducing the Affinity Binder Knockdown Initiative - a public–private partnership for validation of affinity reagents
Publication date: Available online 7 January 2016 Source:EuPA Open Proteomics Author(s): Tove Alm, Emma Lundberg, Mathias Uhlén The newly launched Affinity Binder Knockdown Initiative encourages antibody suppliers and users to join this public-private partnership, which uses crowdsourcing to collect characterization data on antibodies. Researchers are asked to share validation data from experiments where gene-editing techniques (such as siRNA or CRISPR) have been used to verify antibody binding. The initiative is launched under the aegis of Antibodypedia, a database designed to allow comparisons and scoring of public...
Source: EuPA Open Proteomics - January 11, 2016 Category: Bioinformatics Source Type: research

Abstract B45: c-MYC is a potential therapeutic target for cisplatin-resistant ovarian cancer
Ovarian cancer accounts for approximately 3% of all cancers in women. However, it is the deadliest cancer of the female reproductive system. Due to its non-specific symptoms, ovarian cancer is diagnosed at advanced stages of the disease. The most common standard treatment for advanced ovarian cancer is the platinum-based drugs such as cisplatin. However, over 70% of women relapse due to chemoresistance. Several mechanisms of cisplatin resistance have been described. However, the exact mechanism is not known. Evidence indicates that activation of the transcription factor c-MYC and its regulated genes could be involved in su...
Source: Molecular Cancer Research - October 18, 2015 Category: Cancer & Oncology Authors: Vivas-Mejia, P. E., Reyes, j., Sood, A. K. Tags: Therapeutic Translation: Poster Presentations - Proffered Abstracts Source Type: research